• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Anti-CD19 CAR-T Cells as First-Line Therapy for High-Risk Large B-Cell Lymphoma

June 7, 2022

Large-B-cell lymphoma (LBCL) is one of the most common types of non-Hodgkin lymphoma, and many patients do not respond well to standard first-line chemoimmunotherapy regimes.  Notably, complete response rates for disappearance of all cancer in patients with high-risk LBCL are less than 60%; high-risk LBCL is characterized by positive positron emission tomography-computed tomography (PET-CT) and gene rearrangements of MYC and BCL2 and/or BCL6 (i.e. double- or triple-hit lymphomas).  Chimeric antigen receptor (CAR) T-cells are a promising therapy used to treat hematological cancers by targeting CD-19, a biomarker for B-cells.  Axicabtagene ciloleucel (axi-cel), an anti-CD-19 CAR T-cell therapy, has been approved for patients with refractory LBCL, and the results of the ZUMA-12 phase 2 single-arm, multi-center trial suggest that axi-cel may be helpful as a first-line therapy in this population.  During 2019-2020, axi-cel was made and administered to 40 of the 42 patients enrolled in the study with a complete response rate of 78% (95% C.I., 62-90).  Furthermore, the adverse events were manageable.  Additional research is needed to confirm these results, but CAR-T cell therapies may also be helpful as a therapy for some lower-risk patients with LBCL.

Reference:

1. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, et al.  Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma:  the phase 2 ZUMA-12 trial.  Nature Medicine 2022; 28; 735-742

Filed Under

  • Cell Therapy
  • News

Recommended

  • Albumin/Fresh Frozen Plasma Combination May be Effective for Plasma Exchange of TTP Patients

  • Carnitine Metabolism Associated with Red Blood Cell Hemolysis

  • Limited Data for Plasmapheresis to Treat Post-COVID-19 Condition

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley